Dana­her’s third-quar­ter rev­enue from biotech ser­vices down 19% amid slow­down in Chi­na, US

An an­tic­i­pat­ed re­duc­tion in biotech sales con­tributed to Dana­her’s third-quar­ter per­for­mance drop­ping rel­a­tive to last year, the com­pa­ny re­vealed Tues­day. This is in the midst of biotech’s broad­er loss of mo­men­tum in key mar­kets.

The life sci­ence com­pa­ny’s rev­enues from biotechs plum­met­ed by 19% from the same quar­ter last year to $1.66 bil­lion, ac­cord­ing to Za­cks Eq­ui­ty Re­search. A “mod­est step down” in phar­ma and biotech saw big cus­tomers tight­en their belts in the US and Chi­na, CEO Rain­er Blair added on an earn­ings call Tues­day, as per an Al­phaSense tran­script.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER